A1c

A new study has found that three quarters of individuals with type 2 diabetes ( T2D ) who were treated...


The FDA ( U.S. Food and Drug Administration ) has approved Rybelsus ( Semaglutide ) oral tablets to improve control...


The aim of study was to investigate the efficacy, safety, and tolerability of oral Semaglutide ( Rybelsus ) added to...


The European Commission has granted marketing authorization for Zynquista ( Sotagliflozin ), at once-daily doses of 200 mg and 400...


The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in...


Dulaglutide ( Trulicity ) significantly improves A1C ( average blood sugar concentration over two to three months ) when added...


The results from PIONEER 8, a phase 3a trial with oral Semaglutide ( Rybelsus ) for the treatment of adults with...


A study has assessed the efficacy and safety of iGlarLixi ( a titratable, fixed-ratio combination of Insulin glargine [ iGlar...


Researchers have systematically evaluated the efficacy and safety of Lixisenatide ( Lyxumia ) in patients with type 2 diabetes mellitus. Fourteen...


Findings from two phase 3a clinical trials for Semaglutide, an investigational glucagon-like peptide-1 ( GLP-1 ) analogue, were presented at...


The pivotal inTandem1 phase 3 clinical trial of Sotagliflozin met its primary endpoint, showing a statistically significant reduction in A1C...


Cardiovascular autonomic diabetic neuropathy ( CAN ) is a serious complication of diabetes. No reliable data on the prevalence of...


Omarigliptin, an investigational once-weekly DPP-4 inhibitor in development for adults with type 2 diabetes, has achieved its primary efficacy endpoint...


Although assessment of cardiovascular safety is mandated by regulatory agencies for the development of new drugs to treat type 2...


Metabolic surgery is a novel therapy for mild obesity ( BMI 30-35 Kg/m2 ) in type 2 diabetes mellitus (...


Type 2 diabetes and obesity impair kidney function. Researchers have examined their respective contributions to urinary albumin excretion ( UAE...


The results from SUSTAIN-1, the first phase 3a trial for Semaglutide, a new GLP-1 analogue administered once-weekly were presented. The...


Empagliflozin is an oral selective SGLT-2 inhibitor that acts by blocking the reabsorption of glucose in the proximal tubules in...


The aim was to assess the efficacy and safety of Dapagliflozin ( Forxiga ) as add-on therapy in patients with...


About 60% of patients with type 2 diabetes mellitus achieve remission after Roux-en-Y gastric bypass ( RYGB ) surgery. No...